SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rosa M. Martín Mateos, Víctor F. Moreira Vicente, Eduardo Tavío Hernández, Jose Luis Cuño Roldán, Luis Téllez Villajos, Marta Aicart Ramos, Julia Arribas Anta, Celia Zaera de la Fuente, Agustín Albillos Martínez, ¿Es posible suspender el tratamiento con antivirales orales en los pacientes con hepatitis crónica B antígeno e negativa? Experiencia y nuevas expectativas, Gastroenterología y Hepatología, 2015, 38, 5, 305

    CrossRef

  2. 2
    Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld, Ningping Zhang, Qin Zhang, Fehmi Tabak, Adrian Streinu-Cercel, Ji-Yao Wang, Ramazan Idilman, Hendrik W. Reesink, Mircea Diculescu, Krzysztof Simon, Mihai Voiculescu, Meral Akdogan, Wlodzimierz Mazur, Jurrien G.P. Reijnders, Elke Verhey, Bettina E. Hansen, Harry L.A. Janssen, Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study), Hepatology, 2015, 61, 5
  3. 3
    Ming-Ling Chang, Wen-Juei Jeng, Yun-Fan Liaw, Clinical Events After Cessation of Lamivudine Therapy in Patients Recovered From Hepatitis B Flare With Hepatic Decompensation, Clinical Gastroenterology and Hepatology, 2015, 13, 5, 979

    CrossRef

  4. 4
    Chih-Chien Yao, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Mei-Chin Hsu, Chien-Hung Chen, Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion, Journal of Gastroenterology and Hepatology, 2015, 30, 5
  5. 5
    Michelle Martinot-Peignoux, Tarik Asselah, Patrick Marcellin, HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients, Liver International, 2015, 35,
  6. 6
    Tung-Hung Su, Jia-Horng Kao, Improving clinical outcomes of chronic hepatitis B virus infection, Expert Review of Gastroenterology & Hepatology, 2015, 9, 2, 141

    CrossRef

  7. 7
    S. J. Hadziyannis, Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2015, 41, 2
  8. 8
    Mauro Viganò, Federica Invernizzi, Pietro Lampertico, Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?, Liver International, 2015, 35,
  9. 9
    P. Lampertico, Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?, Gut, 2015, 64, 4, 526

    CrossRef

  10. 10
    Anna S. Lok, Personalized treatment of hepatitis B, Clinical and Molecular Hepatology, 2015, 21, 1, 1

    CrossRef

  11. You have free access to this content11
    H. Chi, B. E. Hansen, C. Yim, P. Arends, M. Abu-Amara, A. A. Eijk, J. J. Feld, R. J. Knegt, D. K. H. Wong, H. L. A. Janssen, Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2015, 41, 9
  12. 12
    W.-K. Seto, A. J. Hui, V. W.-S. Wong, G. L.-H. Wong, K. S.-H. Liu, C.-L. Lai, M.-F. Yuen, H. L.-Y. Chan, Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study, Gut, 2015, 64, 4, 667

    CrossRef

  13. 13
    Jianhui Qu, Zujiang Yu, Qin Li, Yongping Chen, Dedong Xiang, Lin Tan, Chunliang Lei, Wenlin Bai, Hongyan Li, Qinghua Shang, Liang Chen, Xiaoyu Hu, Wei Lu, Zhiqin Li, Da Chen, Xiaodong Wang, Changjiang Zhang, Guangming Xiao, Xun Qi, Jing Chen, Li Zhou, Guofeng Chen, Yonggang Li, Zhen Zeng, Guanghua Rong, Zheng Dong, Yan Chen, Min Lou, Chunping Wang, Yinying Lu, Cuihong Zhang, Yongping Yang, Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial, Trials, 2014, 15, 1, 438

    CrossRef

  14. 14
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, Vassilios Sevastianos, Emilia Hadziyannis, Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?, Current Hepatology Reports, 2014, 13, 3, 256

    CrossRef

  15. 15
    Angeline Oi-Shan Lo, Grace Lai-Hung Wong, Current developments in nucleoside/nucleotide analogues for hepatitis B, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 607

    CrossRef

  16. 16
    Jonathan Skupsky, Ke-Qin Hu, Current hepatitis B treatment guidelines and future research directions, Frontiers of Medicine, 2014, 8, 2, 145

    CrossRef

  17. 17
    Wen-Juei Jeng, Finite entecavir therapy is a feasible alternative to indefinite therapy, Hepatology, 2014, 60, 5
  18. You have free access to this content18
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico, HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?, Liver International, 2014, 34,
  19. 19
    Ming-Ling Chang, Yun-Fan Liaw, Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management, Journal of Hepatology, 2014, 61, 6, 1407

    CrossRef

  20. 20
    Christian Trépo, Henry L Y Chan, Anna Lok, Hepatitis B virus infection, The Lancet, 2014, 384, 9959, 2053

    CrossRef

  21. 21
    Keunhee Kang, Ji Hoon Kim, Is HBsAg Loss an Ideal End-point of Oral Antiviral Therapy in Chronic Hepatitis B Patients?, The Korean Journal of Gastroenterology, 2014, 63, 5, 329

    CrossRef

  22. You have free access to this content22
    Cristina Pérez-Cameo, Mònica Pons, Rafael Esteban, New therapeutic perspectives in HBV: when to stop NAs, Liver International, 2014, 34,
  23. 23
    Hyung Sohn, Bo Min, Joon Song, Mun Seong, Sang Lee, Eun Jang, Cheol Shin, Young Park, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Lee, Jin-Wook Kim, Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs, BMC Infectious Diseases, 2014, 14, 1, 439

    CrossRef

  24. 24
    Gin-Ho Lo, The Use of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen–Positive Patients With Normal Levels of Alanine Aminotransferase, Gastroenterology, 2014, 147, 3, 718

    CrossRef

  25. 25
    V. R. Patwardhan, N. Sengupta, A. Bonder, D. Lau, N. H. Afdhal, Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides, Alimentary Pharmacology & Therapeutics, 2014, 40, 7
  26. 26
    Jurriën G.P. Reijnders, Harry L.A. Janssen, Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty?, Hepatology, 2013, 58, 6